GoodRx Holdings Announces Director and Executive Changes
Ticker: GDRX · Form: 8-K · Filed: Feb 5, 2025 · CIK: 1809519
| Field | Detail |
|---|---|
| Company | Goodrx Holdings, Inc. (GDRX) |
| Form Type | 8-K |
| Filed Date | Feb 5, 2025 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $500,000, $250,000, $3,500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation
Related Tickers: GDRX
TL;DR
GoodRx shakes up board and exec pay - new faces, new comp plans.
AI Summary
GoodRx Holdings, Inc. announced on February 4, 2025, changes related to its board of directors and executive compensation. Specifically, the filing details the departure of certain officers and directors, the election of new directors, and adjustments to compensatory arrangements for key executives. The company is incorporated in Delaware and headquartered in Santa Monica, California.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, potentially impacting investor confidence and stock performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation structures can introduce uncertainty regarding future strategy and performance.
Key Players & Entities
- GoodRx Holdings, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- Santa Monica, California (location) — Principal Executive Offices
FAQ
What specific roles have been affected by the departure of officers or directors?
The filing indicates the departure of certain officers and directors, but does not specify the exact roles in this summary.
When did the reported events take place?
The earliest event reported is dated February 4, 2025.
What are the main items covered in this 8-K filing?
This filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers, as well as financial statements and exhibits.
Where is GoodRx Holdings, Inc. headquartered?
GoodRx Holdings, Inc. is headquartered at 2701 Olympic Boulevard, Santa Monica, California.
What is the Commission File Number for GoodRx Holdings, Inc.?
The Commission File Number for GoodRx Holdings, Inc. is 001-39549.
Filing Stats: 1,412 words · 6 min read · ~5 pages · Grade level 11.6 · Accepted 2025-02-05 16:09:18
Key Financial Figures
- $0.0001 — hich registered Class A Common Stock, $0.0001 par value per share GDRX The Nasda
- $500,000 — ovides for (i) an annual base salary of $500,000; and (ii) eligibility to participate in
- $250,000 — d to receive a one-time cash payment of $250,000 (the "Signing Bonus"). In the event th
- $3,500,000 — nit award having an aggregate value of $3,500,000 (the "Initial RSU Award") and (ii) a st
Filing Documents
- gdrx-20250204.htm (8-K) — 94KB
- exhbit101-goodrxxemploymen.htm (EX-10.1) — 757KB
- 0001809519-25-000021.txt ( ) — 1051KB
- gdrx-20250204.xsd (EX-101.SCH) — 2KB
- gdrx-20250204_lab.xml (EX-101.LAB) — 21KB
- gdrx-20250204_pre.xml (EX-101.PRE) — 12KB
- gdrx-20250204_htm.xml (XML) — 3KB
02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Chief Financial Officer and Treasurer Appointment On February 4, 2025, the Board of Directors (the "Board") of GoodRx Holdings, Inc. (the "Company") appointed Christopher A. McGinnis as Chief Financial Officer and Treasurer of the Company, effective as of his commencement of employment, which occurred on February 4, 2025 (the "Effective Date"). Mr. McGinnis succeeds Romin Nabiey who, as previously disclosed, has been serving as Interim Chief Financial Officer. Mr. Nabiey will continue to serve as the Company's Chief Accounting Officer and principal accounting officer. Prior to the Effective Date, Mr. McGinnis, 53, served as Chief Executive Officer of Citizens Rx LLC ("Citizens Rx"), a pharmacy benefits manager, from May 2021 until December 2024, where he set the strategic direction for the company, successfully oversaw its operations, and built a performance-driven executive team. From May 2017 to May 2021, Mr. McGinnis held various executive roles at Lumeris / Essence Healthcare, a Medicare Advantage health plan and value-based care operator, including roles as Chief Financial Officer, where he led the financial strategy and operations of the organization, and Executive Vice President of Operations. Prior to that, from March 2008 to May 2017, Mr. McGinnis served in various roles at Express Scripts Holding Company, a pharmacy benefit management organization, including serving as its Chief Accounting Officer and Principal Accounting Officer. Mr. McGinnis holds a B.S. degree in Accountancy from the Missouri State University and a Juris Doctorate degree from St. Louis University. There are no transactions in which the Company is a party and in which Mr. McGinnis has a material interest subject to disclosure under Item 404(a) of Regulation S-K. There are no family relationships between Mr. McGinni
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits . The following exhibits are included with this Current Report on Form 8-K: 10.1 Employment Agreement, by and between GoodRx Holdings, Inc., GoodRx, Inc. and Christopher A. McGinnis, dated February 4, 2025 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GOODRX HOLDINGS, INC. Date: February 5, 2025 By: /s/ Wendy Barnes Name: Wendy Barnes Title: Chief Executive Officer and President